Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TJP2 |
| Gene Name: | TJP2 |
| Protein Full Name: | Tight junction protein Zonula occludens protein 2 |
| Alias: | Friedreich ataxia region gene X104; Tight junction protein 2; Tight junction protein 2 (zona occludens 2); Tight junction protein ZO-2; X104; ZO2; ZO-2; Zona occludens 2 protein; Zona occludens protein 2; Zonula occludens 2 protein; Zonula occludens protein 2 |
| Mass (Da): | 133972 |
| Number AA: | 1190 |
| UniProt ID: | Q9UDY2 |
| Locus ID: | 9414 |
| COSMIC ID: | TJP2 |
| Gene location on chromosome: | 9q13-q21; 9q21.11 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19651 |
| Percent of cancer specimens with mutations: | 0.79 |
| Gene undergoes hypermethylation: | Pancreatic adenocarcinoma, Prostate adenocarcinoma |
| Normal role description: | TJP2 is a protein involved in the assembly of tight junctions between epithelial/endothelial cells. TJP2 will form homoter/hetero dimers across adjacent cells to form tight junctions and anchor cells to the cytoskeleton. In conditions of stress TJP2 can translocate to the nucleus where it can inhibit cell cycle progression through preventing transcription of cyclin D1. TJP2 has been proposed to act as a tumour suppressor protein as downregulation by promoter hypermethylation has been observed in many cancers including; pancreatic, prostate, breast, lung, and testicular cancers. |
| Commentary on involvement of protein in cancer: | Less than 3% mutation in CNS. |